Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 16/20 | 0.65 |
| ▸ | EGFR | P00533 | 1/20 | 0.64 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.64 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.62 |
| ▸ | WNT1 | P04628 | 1/20 | 0.62 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.61 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.61 |
| ▸ | NQO2 | P16083 | 2/20 | 0.54 |
| ▸ | PIP4K2C | Q8TBX8 | 2/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.53 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.53 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.53 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13355086 | 0.88 | MET (0.62) | METEGFRERBB2ERBB4NPC1 | |
| SCHEMBL29870164 | 0.81 | WNT1 (0.55) | METDYRK1AWNT1 | |
| SCHEMBL26175363 | 0.80 | ALK (0.57) | METEGFRERBB2ERBB4 | |
| SCHEMBL30828787 | 0.80 | MET (0.62) | METEGFRERBB2ERBB4NPC1 | |
| SCHEMBL30743 | 0.80 | NPC1 (1.00) | NPC1POLBRAB9ADYRK1A | |
| SCHEMBL29757180 | 0.80 | NPC1 (1.00) | NPC1POLBRAB9ADYRK1A | |
| SCHEMBL30964876 | 0.79 | ABL1 (0.52) | METDYRK1AWNT1ABL1 | |
| SCHEMBL23916248 | 0.79 | DYRK1A (0.80) | DYRK1AWNT1 | |
| SCHEMBL32665275 | 0.79 | DYRK1A (1.00) | DYRK1AWNT1 | |
| SCHEMBL20948274 | 0.79 | DYRK1A (0.80) | DYRK1AWNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630770-B1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | RELAY THERAPEUTICS INC (US) | 2024-08-28 | — | — | EP | disclosed |
| US-11591336-B2 | Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors | D. E. SHAW RESEARCH, LLC (US) | 2023-02-28 | — | — | US | disclosed |
| US-20200172546-A1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | RELAY THERAPEUTICS, INC. | 2020-06-04 | — | — | US | disclosed |
| US-20200172546-A1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | RELAY THERAPEUTICS, INC. | 2020-06-04 | — | — | US | disclosed |
| EP-3630770-A1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | Relay Therapeutics, Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| WO-2018218133-A1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | RELAY THERAPEUTICS, INC. (US) | 2018-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172546-A1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | PTPRJ, PTPN2, PTPN5 | MET 641/4885EGFR 1271/4885ERBB2 243/4885 |
| US-11591336-B2 | Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors | PTPN5, PTPN2, PTPN1 | MET 928/4885EGFR 1367/4885ERBB2 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.